Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ex-Acrobot CEO to head up Reapplix

This article was originally published in Clinica

Executive Summary

Privately-held Danish wound care specialist Reapplix has appointed Graeme Brookes CEO. Mr Brookes previously led robotic technology specialist Acrobot, before it was acquired by UK orthopedics firm Stanmore Implants in 2010. After the takeover, he was Stanmore’s global vice-president for product development and product marketing. Mr Brookes has also held senior roles at Johnson & Johnson and Advanced Medical Solutions. He replaces Reapplix founder Niels Erik Holm, who will become chief operating officer. Birkerød-based Reapplix’s lead product is LeucoPatch, a proprietary biological “patch” that is produced at point of use from a patient’s own blood, and is designed for the management of hard to heal wounds. The patch, which is already CE marked for sale in Europe, is currently being evaluated for the treatment of diabetic foot ulcers in a randomized controlled clinical study. Reapplix is backed by three leading Danish investors, Novo Seeds, SEED Capital and Vækstfonden (The Danish Growth Fund).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT101904

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel